Stocktoria
Definium Therapeutics, Inc. DFTX
Definium Therapeutics, Inc. (DFTX) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-30 | Canaccord Genuity | Buy (main) |
| 2026-06-24 | Jones Trading | Buy (main) |
| 2026-06-23 | Baird | Outperform (main) |
| 2026-06-23 | Needham | Buy (main) |
| 2026-06-22 | Leerink Partners | Outperform (main) |
| 2026-06-22 | Oppenheimer | Outperform (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.801 |
| Retained earnings / assets | -1.324 |
| EBIT / assets | -0.378 |
| Equity / liabilities | 3.084 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| DFTX | Definium Therapeutics, Inc. | 1/9 | 1.64 | — | — |
| TRLV | Trulieve Cannabis Corp. | 4/9 | 1.09 | — | -0.4% |
| USNA | USANA HEALTH SCIENCES INC | 6/9 | 7.37 | 32.6 | +8.3% |
| TLRY | Tilray Brands, Inc. | 4/9 | -11.01 | — | +11.5% |
| CRLBF | Cresco Labs Inc. | 3/9 | -2.99 | — | -9.5% |
| AAWH | Ascend Wellness Holdings, Inc. | 4/9 | -1.32 | — | -10.9% |
| CGC | Canopy Growth Corp | 4/9 | — | — | +10.5% |
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
FAQ
Is DFTX financially healthy?
Definium Therapeutics, Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does DFTX pay a dividend?
No, Definium Therapeutics, Inc. does not currently pay a dividend.
How profitable is DFTX?
In FY2025, Definium Therapeutics, Inc. had a return on equity of -55.3%.
What is the analyst price target for DFTX?
The average Wall-Street price target for Definium Therapeutics, Inc. is $55.87, about 30.6% above the recent price, from 15 analysts (consensus: strong buy).
Is DFTX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Definium Therapeutics, Inc.: a Piotroski F-score of 1/9, an Altman Z″ in the grey zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.